Insulet Stock Price, News & Analysis (NASDAQ:PODD)

Insulet trades on the NASDAQ under the ticker symbol "PODD."

Insulet Co. (NASDAQ:PODD) released its quarterly earnings data on Monday, August, 5th. The medical instruments supplier reported $0.02 EPS for the quarter, missing the consensus estimate of $0.03 by $0.01. The medical instruments supplier earned $177.10 million during the quarter, compared to analysts' expectations of $163.63 million. Insulet had a return on equity of 7.85% and a net margin of 2.66%. Insulet's quarterly revenue was up 42.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.03) earnings per share. View Insulet's Earnings History.

Insulet is scheduled to release their next quarterly earnings announcement on Tuesday, November 5th 2019. View Earnings Estimates for Insulet.

Insulet will be holding an earnings conference call on Tuesday, November 5th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Insulet updated its third quarter 2019 earnings guidance on Monday, August, 5th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $174-181 million, compared to the consensus revenue estimate of $172.7 million.

14 equities research analysts have issued 12-month price objectives for Insulet's shares. Their forecasts range from $100.00 to $185.00. On average, they expect Insulet's stock price to reach $145.36 in the next twelve months. This suggests that the stock has a possible downside of 7.1%. View Analyst Price Targets for Insulet.

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last year. There are currently 7 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Insulet.

News stories about PODD stock have trended neutral this week, according to InfoTrie. The research group ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Insulet earned a media sentiment score of 0.2 on InfoTrie's scale. They also assigned media headlines about the medical instruments supplier a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Insulet.

Insulet saw a increase in short interest during the month of September. As of September 30th, there was short interest totalling 4,710,000 shares, an increase of 13.8% from the August 30th total of 4,140,000 shares. Based on an average trading volume of 903,900 shares, the short-interest ratio is currently 5.2 days. Currently, 7.9% of the company's shares are sold short. View Insulet's Current Options Chain.

Some companies that are related to Insulet include FRESENIUS SE &/S (FSNUY), ResMed (RMD), Teleflex (TFX), DexCom (DXCM), ABIOMED (ABMD), Novocure (NVCR), Hill-Rom (HRC), Haemonetics (HAE), Integra Lifesciences (IART), Penumbra (PEN), Globus Medical (GMED), Tandem Diabetes Care (TNDM), NuVasive (NUVA), ICU Medical (ICUI) and Cantel Medical (CMD).

Based on aggregate information from My MarketBeat watchlists, some companies that other Insulet investors own include DexCom (DXCM), Tandem Diabetes Care (TNDM), Alibaba Group (BABA), NVIDIA (NVDA), Netflix (NFLX), Splunk (SPLK), ServiceNow (NOW), Coupa Software (COUP), EXACT Sciences (EXAS) and salesforce.com (CRM).

Insulet's stock is owned by many different of institutional and retail investors. Top institutional investors include Envestnet Asset Management Inc. (0.04%), CIBC Private Wealth Group LLC (0.02%), Gradient Investments LLC (0.02%), First Hawaiian Bank (0.01%), First Citizens Bank & Trust Co. (0.01%) and HMS Capital Management LLC (0.00%). Company insiders that own Insulet stock include Aiman Abdel-Malek, Bradley A Thomas, Charles Alpuche, David A Lemoine, David Colleran, James C Mullen, John A Fallon, Michael L Levitz, Michael P Spears, Sally Crawford and Shacey Petrovic. View Institutional Ownership Trends for Insulet.

PODD stock was sold by a variety of institutional investors in the last quarter, including CIBC Private Wealth Group LLC. Company insiders that have sold Insulet company stock in the last year include Aiman Abdel-Malek, Charles Alpuche, David A Lemoine, David Colleran, John A Fallon, Michael L Levitz, Michael P Spears, Sally Crawford and Shacey Petrovic. View Insider Buying and Selling for Insulet.

PODD stock was purchased by a variety of institutional investors in the last quarter, including First Citizens Bank & Trust Co., First Hawaiian Bank, Envestnet Asset Management Inc., Meeder Asset Management Inc., Cerebellum GP LLC, Juncture Wealth Strategies LLC, Wedbush Securities Inc. and Gradient Investments LLC. View Insider Buying and Selling for Insulet.

Shares of PODD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of PODD stock can currently be purchased for approximately $156.49.

Insulet has a market capitalization of $9.43 billion and generates $563.82 million in revenue each year. The medical instruments supplier earns $3.29 million in net income (profit) each year or $0.05 on an earnings per share basis. Insulet employs 1,169 workers across the globe.View Additional Information About Insulet.

The official website for Insulet is http://www.insulet.com/.

Insulet's mailing address is 100 NAGOG PARK, ACTON MA, 01720. The medical instruments supplier can be reached via phone at 978-600-7000 or via email at [email protected]